Phase I/II Trial of Carboxyamidotriazole Orotate (CTO) Alone or in Combination with Lomustine for Bevacizumab-Niave patients with Recurrent WHO grade IV Malignant Glioma. Study#2
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Tactical Therapeutics, Inc.
Start Date
October 1, 2013
End Date
November 3, 2016
Administered By
Duke Cancer Institute
Awarded By
Tactical Therapeutics, Inc.
Start Date
October 1, 2013
End Date
November 3, 2016